Celltrion chairman\
Scope
Date
~
-
Bio & Pharma
Celltrion to supply Remsima, Herzuma to Peru
South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...
May 02, 2024 (Gmt+09:00)
-
Corporate strategy
POSCO tightens belts, seeks M&A within 3 years: new chairman
Chang In-hwa, chairman and chief executive of POSCO Holdings Inc., the parent of South Korea’s top steelmaker POSCO, has vowed to take drastic...
Apr 23, 2024 (Gmt+09:00)
-
Electric vehicles
Hyundai Motor, Matrix Renewables in solar deal to power Georgia EV plant
South Korea’s top automaker Hyundai Motor Group said on Monday it has signed a 15-year power purchase contract with a US solar energy generati...
Apr 22, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion releases Remsima SC in Denmark
South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...
Apr 19, 2024 (Gmt+09:00)
-
Bio & Pharma
Korea’s Celltrion, SK Biopharmaceuticals benefit from direct US sales
Celltrion Inc. and SK Biopharmaceuticals Co. are witnessing improving sales revenue and profitability by selling their products through their own ma...
Apr 16, 2024 (Gmt+09:00)
-
Private equity
Hahn & Co. overhauls Namyang board, ending family control
Private equity firm Hahn & Co. on Friday won shareholder approval to replace Namyang Dairy Products Co.'s board of directors with Hahn's executi...
Mar 29, 2024 (Gmt+09:00)
-
Batteries
POSCO new chief vows to keep fostering battery materials business
POSCO Holdings Inc.'s new Chairman Chang In-hwa on Thursday pledged to keep fostering its electric vehicle battery materials business, the group&rsq...
Mar 21, 2024 (Gmt+09:00)
-
Corporate governance
Lotte Group to give more authority to outside directors
Food-to-retail conglomerate Lotte will expand the authority of outside directors by separating the roles of chief executives and board chairs at its...
Mar 20, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion'a autoimmune disease drug Zymfentra makes US debut
South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...
Mar 18, 2024 (Gmt+09:00)
-
Shareholder activism
ISS backs Kumho Petrochem in family feud-triggered proxy war
Proxy advisory firm International Shareholder Services (ISS) has expressed its support for all of Kumho Petrochemical Co.'s proposals up for vote ...
Mar 12, 2024 (Gmt+09:00)
-
Chief Executives
Chung Yong-jin, now chairman, to bring Shinsegae back from doldrums
Chung Yong-jin, vice chairman of South Korea’s retail giant Shinsegae Group, has been promoted to chairman to strengthen his clout over the co...
Mar 08, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion ships initial supply of Zymfentra to US
South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...
Feb 29, 2024 (Gmt+09:00)
-
Artificial intelligence
Meta’s Zuckerberg to visit Korea on possible AI partnership
Mark Zuckerberg, chief executive of US tech giant Meta Platforms Inc. plans to visit South Korea later this month and meet key figures including Pre...
Feb 21, 2024 (Gmt+09:00)
-
Leadership & Management
Family feud at Kumho Petrochem set to reignite
Park Chul-whan, the nephew of Kumho Petrochemical Co.'s former Chairman Park Chan-koo, has launched a proxy fight jointly with an activist fund, fue...
Feb 15, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to deliver three treatments to Peru
South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) t...
Feb 15, 2024 (Gmt+09:00)
-
Steel
POSCO chairman nominee to prop up ailing steel business
The chairman nominee of POSCO Holdings Inc., the parent of the world’s No. 7 steelmaker POSCO, is expected to concentrate on improving its cor...
Feb 13, 2024 (Gmt+09:00)
-
Leadership & Management
POSCO taps ex-President Chang In-hwa as its next group chairman
POSCO Holdings Inc., the parent of South Korea’s largest steelmaker POSCO, has nominated former President Chang In-hwa as its next group chair...
Feb 08, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply Remsima SC, Yuflyma to Norway
South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...
Feb 07, 2024 (Gmt+09:00)
-
Venture capital
SK Networks ties up with US-based Bow Capital for investments
SK Networks Co., a South Korean trading company, joined hands with Silicon Valley-based venture capital firm Bow Capital for investment cooperation,...
Jan 31, 2024 (Gmt+09:00)
-
Corporate restructuring
Lotte Group Chairman says to sell ailing units for new biz: report
Lotte Group plans to sell ailing units as the South Korean retail-to-chemical conglomerate is shifting its focus to new growth sectors such as bio, ...
Jan 30, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion, WuXi XDC to develop new antibody-drug conjugates
South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC)...
Jan 24, 2024 (Gmt+09:00)
-
Korean stock market
Korea’s ELS market to stagnate after HSCEI debacle: KOFIA chairman
The Korea Financial Investment Association (KOFIA) will go all out to minimize any adverse effects on the South Korean financial market from an anti...
Jan 23, 2024 (Gmt+09:00)
-
Banking & Finance
Woori Financial to bolster private banking service: chairman
Woori Financial Group, South Korea’s fourth-largest financial holding company, will reinforce its wealth management service for high-net-worth...
Jan 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to export three anticancer drugs to Europe
South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...
Jan 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion Holdings eyes Nasdaq IPO by early 2025: chairman
South Korean biosimilar giant Celltrion Group is planning to debut on the Nasdaq market by early 2025, founder and Chairman Seo Jung-jin said at the...
Jan 16, 2024 (Gmt+09:00)
-
Mergers & Acquisitions
OCI-Hanmi merger to create Korea’s Bayer: OCI Chairman
Merging into one team, OCI Group and Hanmi Pharmaceutical Group will leap forward to be a global novel drug manufacturing and biotechnology innova...
Jan 15, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to expand Yuflyma supply network in Europe
South Korea’s Celltrion Inc. announced on Friday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatment ...
Jan 12, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion revises up earnings goals to overtake Amgen
Celltrion Inc., South Korea's leading biosimilar maker, on Wednesday expressed its ambition to join the global top 10 biotech and pharmaceutical com...
Jan 11, 2024 (Gmt+09:00)
-
Samsung Group
Samsung heirs tap $2.1 bn block sale for inheritance taxes
The heirs of late Samsung Group Chairman Lee Kun-hee are seeking to sell their shares in Samsung Electronics Co. and other Samsung affiliates worth ...
Jan 10, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for interchangeability of Yuflyma in US
South Korea's Celltrion Inc. announced on Wednesday that it has applied to the US Food and Drug Administration (FDA) for a modified approval to repl...
Jan 10, 2024 (Gmt+09:00)